Clinical trial
A Phase II Investigation of Bevacizumab for the Treatment of Second-Look Positive Epithelial Ovarian Cancer
NCT02884648 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Investigation of Bevacizumab for the Treatment of Second-Look Positive Epithelial Ovarian Cancer
- Lead sponsor
- M.D. Anderson Cancer Center
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- November 15, 2016
- Completion date
- February 2, 2027
- Enrollment
- 35 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
fallopian tube cancer, malignant neoplasms of female genital organs, ovarian cancer, primary peritoneal cancer